Pre-made Tanezumab benchmark antibody ( Whole mAb, anti-NGFB/NGF therapeutic antibody, Anti-HSAN5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-549-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody
INN Name	Tanezumab
Target	NGF
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	4edw:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Rinat Neuroscience;Pfizer
Conditions Approved	na
Conditions Active	Back pain;Cancer pain;Musculoskeletal pain
Conditions Discontinued	Diabetic neuropathies;Postherpetic neuralgia
Development Tech	na